Your browser doesn't support javascript.
loading
The intrapleural administration with thymic peptides in malignant pleural effusion: A clusteredsystematicreview and meta-analysis.
Wang, Cheng-Qiong; Shen, You-Shu; Chen, Xiao-Fan; Jiang, Hong; Yang, Xue-Mei; Fan, Teng-Yang; Li, Shu-Guang; Yang, Ping; Zhan, Lin; Chen, Rong; Feng, Ji-Hong; Xiao, Xue; Xiao, Zheng.
Afiliação
  • Wang CQ; Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China; Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, Chin
  • Shen YS; Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China.
  • Chen XF; Evidence-Based Medicine Research Centre, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, Jiangxi, China.
  • Jiang H; Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China; Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, Chin
  • Yang XM; Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China; Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, Chin
  • Fan TY; Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China.
  • Li SG; Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China.
  • Yang P; Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China.
  • Zhan L; Laboratory Research Center, Guizhou Provincial People's Hospital, Guizhou University, Guiyang 550002, Guizhou, China.
  • Chen R; Department of Infectious Diseases, Anshun People's Hospital, Anshun 561000, Guizhou, China.
  • Feng JH; Department of Oncology, Lishui People's Hospital, Sixth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang, China.
  • Xiao X; Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China; Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, Chin
  • Xiao Z; Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, China; Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou, Chin
Int Immunopharmacol ; 107: 108688, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35293322
ABSTRACT

BACKGROUND:

Thymic peptides (TPs) are often used to control malignant pleural effusion (MPE). So, we performed a clustered systematic review and meta-analysis to clarify the treatment regimens of TPs for MPE, demonstrate their clinical effectiveness and safety, and reveal the indications and optimal usage for a desired effectiveness. MATERIALS AND

METHODS:

We collected all trials of TPs for MPE from Chinese and English databases (from inception until May 2021). After evaluating their bias risk, we pooled the data from each regimen using the meta-analysis or descriptive analysis, and summarized the evidence quality using the Grading of Recommendation Assessment, Development and Evaluation approach (GRADE).

RESULTS:

Thirty-four trials were clustered into TPs for MPE from lung cancer or miscellaneous tumors. The TPs combined with chemical agents were mainly used in MPE from lung cancer. All five regimens, only thymosin with oxaliplatin (L-OHP) significantly improved the complete response (CR) [2.40 (1.84 to 3.13)], quality of life [2.04 (1.20 to 3.48)], 0.5- and 1-year overall survival (OS) rate [5.75 (3.02 to 10.92) and 5.29, (1.71 to 16.36)]. It also up-regulated the T lymphocyte levels, and reduced the pleurodesis failure, disease progression and adverse events. In patients with moderate to large volume, Karnofsky Performance Status score ≥ 50 or anticipated survival time ≥ 3 months, the thymosin (300 mg/time, one time/week and lasting two to eight times) with oxaliplatin (100 mg/m2) achieved a desired response. Most results were moderate quality.

CONCLUSIONS:

The current evidences indicate that the TPs are important pleurodesis agents, which combination with chemical agents are mainly used in MPE from lung cancer. The thymosin with L-OHP is a main regimen, which shows a significant improvement in clinical responses, antitumor immunity, and with a reasonable security. The evidence also provides indications and optimal usage for achieving a desired effectiveness.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Timosina / Derrame Pleural Maligno / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Timosina / Derrame Pleural Maligno / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article